TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
TScan Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
TScan Therapeutics's price to book ratio was 0.3× on Nov 11, 2026, against 1.0× a year earlier. Over the last 4 years it ranged from 0.2× to 5.8×, with a median of 1.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.3× | −0.5 |
| 2025 | Dec 31, 2025 | 0.9× | −0.5 |
| 2024 | Dec 31, 2024 | 1.4× | −0.2 |
| 2023 | Dec 29, 2023 | 1.6× | +1.5 |
| 2022 | Jan 31, 2022 | 0.2× | +0.0 |
| 2021 | Dec 31, 2021 | 0.2× | – |
See a number that looks wrong?